Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK19 | Q9BWU1 | 3/20 | 0.76 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.76 |
| ▸ | IGF1R | P08069 | 11/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | INSR | P06213 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727487 | 0.90 | CDK19 (0.69) | CDK19ALKIGF1REGFRERBB2 | |
| SCHEMBL3767668 | 0.89 | CDK19 (0.81) | CDK19ALKIGF1REGFRERBB2 | |
| SCHEMBL3716630 | 0.86 | CDK19 (0.87) | CDK19ALKIGF1REGFRERBB2 | |
| SCHEMBL3721829 | 0.85 | CDK19 (0.86) | CDK19ALKIGF1REGFRERBB2 | |
| SCHEMBL3756611 | 0.85 | CDK19 (0.73) | CDK19ALKIGF1REGFRERBB2 | |
| SCHEMBL1788724 | 0.85 | CDK19 (0.70) | CDK19ALKIGF1REGFRERBB2 | |
| SCHEMBL1789301 | 0.85 | CDK19 (0.70) | CDK19ALKIGF1REGFRERBB2 | |
| SCHEMBL3766261 | 0.85 | CDK2 (0.62) | CDK19ALKIGF1REGFRERBB2 | |
| SCHEMBL3762589 | 0.84 | CDK19 (0.72) | CDK19ALKIGF1REGFRERBB2 | |
| SCHEMBL3759857 | 0.84 | CDK19 (0.72) | CDK19ALKIGF1REGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435435-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-01-29 | — | — | EP | disclosed |
| US-8536180-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2010138575-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | CDK19 69/4885ALK 701/4885IGF1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.